Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cartesian Therapeutics Inc RNAC

Healthcare Biotechnology
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune... see more

Current News (NDAQ:RNAC)

Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire 7 days ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 23, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire February 3, 2026

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

GlobeNewswire January 9, 2026

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire January 6, 2026

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

GlobeNewswire December 18, 2025

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

GlobeNewswire November 13, 2025

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 6, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants

GlobeNewswire October 30, 2025
View More News ››

Opinion & Analysis (NDAQ:RNAC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RNAC)

Cartesian Therapeutics (NASDAQ:RNAC) – Pioneering mRNA

Looks like RNAC is making some serious moves in the mRNA cell therapy space. Their Descartes-08 for myasthenia gravis is showing killer...
MikeTester - January 23, 2025
View more Bullboard ››

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc., together with its subsidiaries, engages in the design, engineering, manufacture, testing, and distribution of ...
View More »

Podcasts